4.4 Article

Role of Adalimumab Biosimilar in the Treatment of Non-Anterior Uveitis Associated with Behcet's Syndrome

Journal

OPHTHALMOLOGY AND THERAPY
Volume 10, Issue 4, Pages 1129-1135

Publisher

SPRINGER INT PUBL AG
DOI: 10.1007/s40123-021-00387-6

Keywords

Adalimumab; Behcet's syndrome; Biosimilar; Retinal vasculitis; Uveitis

Categories

Ask authors/readers for more resources

The study demonstrates the significant efficacy of SB5 in treating Behcet's syndrome-related uveitis, showing its ability to control inflammation relapses, resolve retinal vasculitis, and preserve visual acuity.
Introduction To evaluate the efficacy of SB5, an adalimumab biosimilar, in the management of Behcet's syndrome (BS)-related uveitis. Methods Data from eight BS patients (16 eyes) with active non-anterior uveitis and/or systemic uncontrolled disease or performing non-medical switch to SB5 were retrospectively collected and analyzed. Results Complete control of uveitis was observed in all 16 eyes without relapses during follow-up. The number of relapses 12 months prior to SB5 initiation and at last follow-up was 100 and 0 per 100 patients/year, respectively (p = 0.010). At baseline, four eyes had active retinal vasculitis, whereas at 3 months and at last follow-up, retinal vasculitis had resolved in all of them (p = 0.018). Median visual acuity did not vary significantly between baseline and last follow-up visit (p = 0.109). No ocular complications emerged during treatment. Conclusions SB5 is effective in the treatment of BS-related non-anterior uveitis. It reduces uveitis relapses and controls retinal vasculitis while allowing preservation of visual acuity.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available